5 registrations that name fluoride as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 5 registrations
Status
Phase
14US sites across 9 states
1
2 to 4
5 to 19
20 or more
All 5 registrations
RecruitingNCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2
National Cancer Institute (NCI)
About 65 people
Started Jun 10, 2022
In plain words A Phase 2 study of fluoride in people 12 and older, run by National Cancer Institute (NCI). It plans to enroll about 65 people at 13 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 12 and older. Conditions: Hereditary Leiomyomatosis and Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma; Sporadic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8.
Patients must have:
A diagnosis of HLRCC with a histologic or cytologic confirmation of RCC consistent with this diagnosis (Cohort 1) OR
Cytologically or histologically confirmed sporadic/non-HLRCC papillary renal cell carcinoma (presence of papillary component) (Cohort 2)
Patients must have advanced RCC with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as…
24 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Atezolizumab; Bevacizumab; Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Computed Tomography with Contrast; Erlotinib; Magnetic Resonance Imaging; Positron Emission Tomography; Sodium Fluoride F-18
Registered summary
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. The full summary is on the listing.
Where, as registered
13 US sites in 9 states.
RecruitingNCT06914999
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Early phase 1
Emory University
About 20 people
Started Dec 3, 2024
In plain words An early phase 1 study of fluoride in people 18 and older, run by Emory University. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8.
Males and females 18 years of age and older
Diagnosis of clinical stage III-IVb (American Joint Committee on Cancer \[AJCC\] 8th edition) squamous cell carcinoma of the oropharynx (human papillomavirus \[HPV\]-negative), larynx, or hypopharynx, or clinical stage I-III (AJCC 8th…
Treatment with concurrent chemoradiotherapy per institutional standard of care at the discretion of Medical Oncology. RT is delivered per institutional standard of care at the discretion of Radiation Oncology
Patients must give protocol-specific consent on an Institutional Review Board (IRB)-approved consent form prior to completion of protocol-specific testing/procedures
5 more inclusion criteria and the exclusion criteria are on the listing.
This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 \[F-18 FDG\] PET/CT) for assessing the effects radiation therapy has on the blood vessels in the neck in patients with head and neck cancers. For people with cancers in the head and neck, doctors often use radiation to target both the tumor and nearby glands. Radiation therapy to this region can affect the blood vessels in the neck that supply blood to the brain. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07873268
Molar-Incisor Hypomineralization and Resin Infiltration
No phase
Hanoi Medical University
About 150 people
Started Oct 2, 2023
In plain words A study of fluoride in people 7 to 11, run by Hanoi Medical University. It plans to enroll about 150 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 7 to 11; healthy volunteers accepted. Conditions: Molar Incisor Hypomineralization.
Children aged 7 to 11 years.
Children diagnosed with mild Molar-Incisor Hypomineralization (MIH) according to EAPD criteria on permanent incisors.
Permanent incisors with intact anatomical shape, showing smooth enamel surfaces or minor defect depth without post-eruptive enamel breakdown (PEB).
Children and parents/guardians willing to participate and sign the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
Resin infiltration; Fluoride Varnishes
Registered summary
This dual-design study-encompassing a cross-sectional descriptive phase and a controlled clinical trial-aims to investigate the prevalence and associated risk factors of Molar Incisor Hypomineralization (MIH), while evaluating the therapeutic efficacy of resin infiltration (ICON) for treating mild MIH lesions in permanent incisors among school children aged 7 to 11 years across selected primary schools in Northern Vietnam. The full summary is on the listing.
Where, as registered
No US site; Vietnam (3).
Not yet recruitingNCT07807397
Oral Hygiene Assistance Training Program
Phase 4
Colgate Palmolive
About 500 people
Starts Sep 20, 2026 (estimated)
In plain words A Phase 4 study of fluoride in people 60 and older, run by Colgate Palmolive. It plans to enroll about 500 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older; healthy volunteers accepted. Conditions: Elderly; Periodontal Disease; Gingivitis; Caries,Dental.
Signed Informed Consent Form to receive on-site dental care and grant access to their medical and dental records, and Consent for information collection, consultation, and disease control oral healthcare treatment
Male and female subjects aged 60 years or older.
A resident of one of the nursing home sites.
ASA physical classification status of II, III, or IV (excluding high frailty scores)
1 more inclusion criterion and the exclusion criteria are on the listing.
This is an oral health study with a nursing home staff training program and product intervention.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06174012
The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC Patients
Phase 2
Sun Yat-sen University
About 135 people
Starts Dec 15, 2023 (estimated)
In plain words A Phase 2 study of fluoride in people 18 to 60, run by Sun Yat-sen University. It plans to enroll about 135 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Sodium Fluoride.
a. Patients with histologically confirmed non-keratinizing NPC (including differentiated type and undifferentiated type, world health organization \[WHO\] II or III). b.
The exclusion criteria are on the listing.
What it tests, as registered
Sodium Fluoride
Registered summary
To evaluate the efficacy of sodium fluoride to preventing radiation caries for patients with nasopharyngeal carcinoma receiving radiotherapy.